Company intelligence / Profile preview

Suzhou Xinda Biotechnology

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

The company is developing a biosimilar to ipilimumab targeting CTLA4 for non-small cell lung cancer, with at least one pipeline program in Phase 2. No summary of clinical trial results is available in the public domain as of June 2025

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiosimilar
Industry: Biotech

Partnerships

Innovent Biologics

Beyond the preview

Go deeper on Suzhou Xinda Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Xinda Biotechnology.

Explore the full profile